OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the European Society for Medical Oncology (ESMO) Virtual Congress 2021
OSE Immunotherapeutics reminds the presentation on positive data of Tedopi® in non-small cell lung cancer today…
O2 and Mavenir successfully trial technology to improve call clarity for people with hearing loss